SCHEMBL10252579

SCHEMBL10252579

Cc1nc(N)c(I)c(Cl)n1

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.32
PDE10A Q9Y233 1/20 0.31
ADORA1 P30542 2/20 0.30
ADORA3 P0DMS8 1/20 0.30
ADORA2A P29274 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29849046 1.00 HTT (0.33) HTTSMN1; SMN2ALDH1A1PDE10AADORA1
SCHEMBL10252220 0.82 TDP1 (0.35)
SCHEMBL14165804 0.75 HTT (0.35) HTTSMN1; SMN2ALDH1A1PDE10AADORA1
SCHEMBL259072 0.75 PDE10A (0.52) HTTSMN1; SMN2ALDH1A1PDE10AADORA1
SCHEMBL29484711 0.75 HTT (0.35) HTTSMN1; SMN2ALDH1A1PDE10AADORA1
SCHEMBL1357635 0.75 DPP4 (0.33) ADORA1ADORA2A
SCHEMBL116212 0.75 HTT (0.37) HTTSMN1; SMN2ALDH1A1PDE10AADORA1
SCHEMBL2549272 0.75 ALDH1A1 (0.35) HTTALDH1A1
SCHEMBL5925922 0.75 TLR8 (0.32) HTTSMN1; SMN2
SCHEMBL4289488 0.75 TDP1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4148056-A1 SOS1 INHIBITOR CONTAINING PHOSPHORUS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-03-15 EP disclosed
WO-2022170802-A1 PYRIMIDO-PYRIDONE DERIVATIVE AS SOS1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 苏州阿尔脉生物科技有限公司 2022-08-18 WO disclosed
CN-107454898-B Ghrelin O-acyltransferase inhibitors 伊莱利利公司 2020-05-05 CN disclosed
US-10227310-B2 Ghrelin 0-acyl transferase inhibitors ELI LILLY AND COMPANY (US) 2019-03-12 US disclosed
US-10227310-B2 Ghrelin 0-acyl transferase inhibitors ELI LILLY AND COMPANY (US) 2019-03-12 US disclosed
US-20180079729-A1 GHRELIN 0-ACYL TRANSFERASE INHIBITORS ELI LILLY AND COMPANY 2018-03-22 US disclosed
US-20180079729-A1 GHRELIN 0-ACYL TRANSFERASE INHIBITORS ELI LILLY AND COMPANY 2018-03-22 US disclosed
US-20180079729-A1 GHRELIN 0-ACYL TRANSFERASE INHIBITORS ELI LILLY AND COMPANY 2018-03-22 US disclosed
EP-3283474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITORS Eli Lilly and Company (US) 2018-02-21 EP disclosed
EP-3068775-B1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR LILLY CO ELI (US) 2017-09-06 EP disclosed
EP-3068775-A1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR Eli Lilly and Company (US) 2016-09-21 EP disclosed
WO-2015073281-A1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY (US) 2015-05-21 WO disclosed
WO-2015073281-A1 SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY (US) 2015-05-21 WO disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-9035051-B1 Ghrelin O-acyl transferase inhibitor ELI LILLY AND COMPANY (US) 2015-05-19 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR ELI LILLY AND COMPANY 2015-05-14 US disclosed
US-20120053053-A1 PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES SYNGENTA CROP PROTECTION, LLC (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227310-B2 Ghrelin 0-acyl transferase inhibitors MBOAT4, GIPR, PLAAT2 HTT 140/4885SMN1; SMN2 4346/4885ALDH1A1 1908/4885
US-20180079729-A1 GHRELIN 0-ACYL TRANSFERASE INHIBITORS MBOAT4, GIPR, PLAAT2 HTT 140/4885SMN1; SMN2 4346/4885ALDH1A1 1908/4885
US-20150133474-A1 GHRELIN O-ACYL TRANSFERASE INHIBITOR MBOAT4, DGAT1, MOGAT2 HTT 201/4885SMN1; SMN2 4584/4885ALDH1A1 1548/4885
US-20120053053-A1 PYRIMIDINE DERIVATIVES AND THEIR USE AS HERBICIDES DPYD, DHODH, TYMP HTT 1560/4885SMN1; SMN2 2864/4885ALDH1A1 1043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.